Korean Circ J.  2020 Jul;50(7):599-609. 10.4070/kcj.2019.0317.

The Clinical Course of Tuberculous Pericarditis in Immunocompetent Hosts Based on Serial Echocardiography

• Kim MS
• Chang SA
• Kim EK
• Choi JO
• Park SJ
• Lee SC
• Park SW
• Oh JK

• KMID: 2504219
• DOI: http://doi.org/10.4070/kcj.2019.0317

Abstract

Background and Objectives
In East Asia, tuberculous pericarditis still occurs in immunocompetent patients. We aimed to investigate clinical course of tuberculous pericarditis and the trends of echocardiographic parameters for constrictive pericarditis.
Methods
We retrospectively analyzed medical records of patients with tuberculous pericarditis between January 2010 and January 2017 in Samsung Medical Center. Treatment consists of the standard 4-drug anti-tuberculosis regimen for 6 months with or without corticosteroids. We performed echocardiography at initial diagnosis, 1, 3 and 6 months later.
Results
Total 50 cases with tuberculous pericarditis in immunocompetent patients were enrolled. Echocardiographic finding at initial diagnosis divided into 3 groups: 1) pericardial effusion only (n=28, 56.0%), 2) effusive constrictive pericarditis (n=10, 20.0%) and 3) constrictive pericarditis (n=12, 24.0%). The proportion of patients with constrictive pericarditis decreased gradually over time. After 6 months, only 5 patients still had constrictive pericarditis. Out of the 28 patients who initially presented with effusion alone, only one patient developed constrictive pericarditis. Echocardiographic parameters representing constrictive pericarditis gradually disappeared over the follow up period. Ventricular interdependency improved significantly from 1 month follow-up, whereas septal bounce and pericardial thickening were still observed after 6 months without significant constrictive physiology.
Conclusions
Tuberculous pericarditis with pericardial effusion without constrictive physiology is unlikely to develop into constrictive pericarditis in immunocompetent hosts, if treated with optimal anti-tuberculous medication and steroid therapy. Even though there were hemodynamic feature of constrictive pericarditis, more than 80% of the patients were improved from constrictive pericarditis.

Keyword

Tuberculous pericarditis; Constrictive pericarditis; Echocardiography; Steroids

Figure

• 

  Figure 1 Initial transthoracic echocardiography. (A) Pericardial effusion without constriction. Large amount of pericardial effusion was noticed (bidirectional arrow). The septal mitral annulus early diastolic velocity (septal e′) was 0.049 m/s (closed arrow). The lateral mitral annulus early diastolic velocity (lateral e′) was 0.078 m/s (open arrow). There was no diastolic flow reversal of the HV. (B) Pericardial effusion with constriction. Small amount of pericardial effusion was observed with pericardial thickening. The septal e′ (0.082 m/s) was higher than the lateral e′ (0.070 m/s). Expiratory diastolic flow reversal of HV was noticed (open arrowhead). (C) Constrictive pericarditis without pericardial effusion. Pericardial thickening was seen (closed arrowhead). The septal e′ (0.164 m/s) was higher than the lateral e′ (0.104 m/s). And also expiratory diastolic flow reversal of HV was noticed (open arrowhead).HV = hepatic vein.

• 

  Figure 2 Proportion of constrictive pericarditis over time. The proportion of patients with constriction decreased through the time. At initial diagnosis, 22 patients (44%) had constrictive pericarditis. After 1 month, the number of patients with constrictive pericarditis was reduced to 12 (27.3%) among 44 patients who underwent echocardiography. Six patients (12.5%) had constrictive pericarditis at 3 months and 5 patients (10%) remained chronic constrictive pericarditis at the end of 6 months for follow-up.

• 

  Figure 3 Clinical course of tuberculous pericarditis. The numbers in blue filled boxes mean the number of patients with constriction at that time. And the numbers in white boxes indicate the number of patients without constriction. Missing data is denoted by M (the number of patients). After 6 months of treatment, residual constrictive pericarditis developed in 4 patients (18.2%) among the 22 patients who initially presented constrictive pericarditis. However, only 1 patient developed residual constrictive pericarditis (3.6%) among 28 patients who initially presented effusion without constriction.

• 

  Figure 4 Resolution of constrictive pericarditis. (A) Initial echocardiography showed constrictive pericarditis with pericardial thickening (closed arrowhead). The septal mitral annulus early diastolic velocity (septal e′) was 0.136 m/s (closed arrow). The septal e′ was higher than the lateral e′ (0.116 m/s, open arrow). Expiratory diastolic flow reversal of the HV was observed dominantly (open arrowhead). In the M mode, ventricular interdependence was prominent. (B) After 6 months, the patients repeated echocardiography. Constrictive pericarditis was resolved. The septal e′(closed arrow) was 0.075 m/s which was lower than the lateral e′ of 0.120 m/s(open arrow). Expiratory diastolic flow reversal of HV was not observed. And also, ventricular interdependence disappeared.HV = hepatic vein.

• 

  Figure 5 Echocardiographic parameters for constriction over time. Ventricular interdependence was the initial parameter of improvement. Septal bouncing and pericardial thickening still remained even after constriction improved.HV = hepatic vein; IVC = inferior vena cava.

Reference

1. Myers RB, Spodick DH. Constrictive pericarditis: clinical and pathophysiologic characteristics. Am Heart J. 1999; 138:219–232. PMID: 10426832.

2. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). G Ital Cardiol (Rome). 2015; 16:702–738. PMID: 26667949.

3. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation. 2005; 112:3608–3616. PMID: 16330703.

4. Harvey A, Whitehill M. Tuberculous pericarditis. Medicine. 1937; 16:45–94.

5. Haley JH, Tajik AJ, Danielson GK, Schaff HV, Mulvagh SL, Oh JK. Transient constrictive pericarditis: causes and natural history. J Am Coll Cardiol. 2004; 43:271–275. PMID: 14736448.

6. Chang SA, Choi JY, Kim EK, et al. [¹⁸F]Fluorodeoxyglucose PET/CT predicts response to steroid therapy in constrictive pericarditis. J Am Coll Cardiol. 2017; 69:750–752. PMID: 28183513.

7. Strang JI, Nunn AJ, Johnson DA, Casbard A, Gibson DG, Girling DJ. Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. QJM. 2004; 97:525–535. PMID: 15256610.

8. Strang JI. Rapid resolution of tuberculous pericardial effusions with high dose prednisone and anti-tuberculous drugs. J Infect. 1994; 28:251–254. PMID: 8089513.

9. Strang JI, Kakaza HH, Gibson DG, et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet. 1988; 2:759–764. PMID: 2901610.

10. Chang SA. Tuberculous and infectious pericarditis. Cardiol Clin. 2017; 35:615–622. PMID: 29025551.

11. Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2013; 26:965–1012.e15. PMID: 23998693.

12. Ha JW, Oh JK, Ling LH, Nishimura RA, Seward JB, Tajik AJ. Annulus paradoxus: transmitral flow velocity to mitral annular velocity ratio is inversely proportional to pulmonary capillary wedge pressure in patients with constrictive pericarditis. Circulation. 2001; 104:976–978. PMID: 11524387.

13. Maisch B, Seferović PM, Ristić AD, et al. Guidelines on the diagnosis and management of pericardial diseases. Executive summary. Rev Esp Cardiol. 2004; 57:1090–1114. PMID: 15544758.

14. Wiysonge CS, Ntsekhe M, Thabane L, et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2017; 9:CD000526. PMID: 28902412.

15. Kadhiravan T, Deepanjali S. Role of corticosteroids in the treatment of tuberculosis: an evidence-based update. Indian J Chest Dis Allied Sci. 2010; 52:153–158. PMID: 20949734.

16. Ntsekhe M, Wiysonge C, Volmink JA, Commerford PJ, Mayosi BM. Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven. QJM. 2003; 96:593–599. PMID: 12897345.